IP Library Granted Patent US 8,053,585
Granted Patent B2
US 8,053,585 · App. 11/402,715 · Granted Nov 8, 2011

Protecting group for carboxylic acids that can be photolyzed by visible light

Assignee: Cornell Research Foundation, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,053,585
App. No.
11/402,715
Granted
Nov 8, 2011
Kind
B2
Abstract

The present invention relates to a photolabile compound including a coumarin family caging group covalently bound to an organic moiety containing a carboxyl group, an amino group, a sulfhydryl group, and/or a hydroxyl group. The photolabile compound, upon absorbing visible light, releases the organic moiety. Also disclosed is a method of making a photolabile compound that releases a biologically active compound upon absorbing visible light by providing an organic moiety and binding a coumarin family caging group to the organic moiety under conditions effective to make the photolabile compound. The present invention also relates to a method of obtaining a biologically active compound in a sample. The method involves adding to a sample a photolabile compound including a coumarin family caging group covalently bound to an organic moiety. The sample is then illuminated with visible light under conditions effective to obtain a biologically active compound including the organic moiety.

Claims (22)

1. A photolabile compound comprising:

a coumarin family caging group covalently bound to an organic moiety containing a carboxyl group, an amino group, a sulfhydryl group, and/or a hydroxyl group, wherein:

the organic moiety is an amino acid selected from the group consisting of: aspartic acid; beta alanine; saclofen; S-sulpho-L-cysteine; γ-N-oxalyl-L-α,γ-diaminobutyric acid; O-phospho-D-serine philanthotoxin 343; (±)-cis-2,3-piperidinedicarboxylic acid; piperidine-4-sulphonic acid; L-trans-pyrrolidine-2,4-dicarboxylic acid; isoguvacine; indole-2-carboxylic acid; (+)-α-methyl-4-carboxyphenylglycine; 6-nitroquinoxaline-2,3-dione; γ-D-glutamylaminoethylphosphonic acid; D-homocysteic acid; L-homocysteinesulphinic acid; (RS)-3-hydroxyphenylglycine; 3-hydroxy-2-quinoxaline-carboxylic acid; 5-7-dichlorokynurenic acid; dihydrokainic acid; domoic acid; L-glutamic acid; (S)-4-carboxyphenylglycine; 6-chlorokynurenic acid; D-cysteic acid; L-cysteine sulphinic acid; (±)-3-carboxyphenylalanine; (R)-5-bromowillardiine; aminomalonic acid; and glycine;

the coumarin family caging group is 7-N,N-diethylamino-4-hydroxymethyl coumarin and is covalently bound to the organic moiety through a hydroxyl group on the coumarin compound and through the carboxyl group, amino group, sulfhydryl group, or hydroxyl group on the organic moiety; and

the photolabile compound, upon absorbing visible light, releases the organic moiety.

2. The photolabile compound according to claim 1 , wherein said organic moiety is caged through the carboxyl group as an ester.

3. The photolabile compound according to claim 1 , wherein said organic moiety is caged through the amino group as a carbamate.

4. The photolabile compound according to claim 1 , wherein said organic moiety is caged through the sulfhydryl group as a thio ether.

5. The photolabile compound according to claim 1 , wherein said organic moiety is caged through the hydroxyl group as an ether or a carbonate of the hydroxyl group.

6. The photolabile compound according to claim 1 , wherein said amino acid is a neurotransmitter.

7. The photolabile compound according to claim 1 having the formula:

or a trifluoroacetate salt or a biologically compatible salt thereof.

8. The photolabile compound according to claim 1 having the formula:

or a trifluoroacetate salt or a biologically compatible salt thereof.

9. The photolabile compound according to claim 1 having the formula:

or a trifluoroacetate salt or a biologically compatible salt thereof.

10. The photolabile compound according to claim 1 having the formula:

or a trifluoroacetate salt or a biologically compatible salt thereof.

11. The photolabile compound according to claim 1 , wherein the compound is water-soluble.

12. The photolabile compound according to claim 1 , wherein the compound is biologically inert.

13. The method according to claim 1 , wherein the organic moiety is a neurotransmitter and is used for kinetically investigating neurotransmitter-receptor interactions on a surface of a cell in a microsecond to millisecond time domain.

14. The method according to claim 1 , wherein the organic moiety is a neurotransmitter and is used for spatially locating neurotransmitter receptors on a cell.

Assignments (3)
CONFIRMATORY LICENSE Recorded Jul 29, 2010
From: CORNELL UNIVERSITY
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 024762/0674 →
EXECUTIVE ORDER 9424, CONFIRMATORY LICENSE Recorded Aug 15, 2008
From: CORNELL UNIVERSITY
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 021397/0510 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 22, 2006
From: HESS, GEORGE P.; CARPENTER, BARRY K.; SHEMBEKAR, VISHAKHA R.; CHEN, YONGLI
To: CORNELL RESEARCH FOUNDATION, INC.
Reel/Frame 017988/0706 →
Continuity (1)
Related Publication 20070243519A1 · Oct 18, 2007